Pioneer in phage-based diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations
Menu
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations

Could a rapid diagnostic help reduce infection risk?

Of the 10 million individuals who became ill with 'active' TB in 2018, approximately three million were missed by health systems, according to the Centres for Disease Control and Prevention (CDC)
  • February 14, 2022
  • Actiphage

Of the 10 million individuals who became ill with ‘active’ TB in 2018, approximately three million were missed by health systems, according to the Centres for Disease Control and Prevention (CDC).

In addition, the actual number of infected individuals might be as high as 1.7billion, due to the ability of the mycobacterium, which causes the disease, to lie dormant in infected individuals without causing illness.

Those who develop active TB disease must take medication to treat the disease and may be asked to self-isolate for 2 weeks or longer. A diagnostic, such as Actiphage, that would allow doctors to more rapidly identify infectious cases of TB could improve detection whilst removing uncertainty.

Share:

Related posts

Loading...
TAG pipeline report on TB feat

Detecting subclinical TB – Actiphage only blood test for mycobacteria highlighted in TAG pipeline report

November 22, 2022
Actiphage is the only test in development for subclinical tuberculosis that directly detects mycobacteria in the blood, it has been revealed by the TAG pipeline report
TAG pipeline report on TB feat

Detecting subclinical TB – Actiphage only blood test for mycobacteria highlighted in TAG pipeline report

November 22, 2022
Actiphage is the only test in development for subclinical tuberculosis that directly detects mycobacteria in the blood, it has been...
ECCMID

Actiphage TB diagnostic finds live mycobacterium tuberculosis in the blood of people with incipient TB

April 23, 2022
A clinical trial of Actiphage, a promising new diagnostic for tuberculosis infection, has shown for the first time that live bacteria can be detected in the blood of people with incipient TB infection.
ECCMID

Actiphage TB diagnostic finds live mycobacterium tuberculosis in the blood of people with incipient TB

April 23, 2022
A clinical trial of Actiphage, a promising new diagnostic for tuberculosis infection, has shown for the first time that live...
ECCMID conference

23-26 April 2022

Novel TB diagnostics paper to be presented at ECCMID 2022

April 4, 2022
Jee-Whang Kim of Leicester Tuberculosis Research Group (LTBRG) is to present a paper in the ‘hot topics in tuberculosis’ session at ECCMID 2022
ECCMID conference

23-26 April 2022

Novel TB diagnostics paper to be presented at ECCMID 2022

April 4, 2022
Jee-Whang Kim of Leicester Tuberculosis Research Group (LTBRG) is to present a paper in the ‘hot topics in tuberculosis’ session...

developers of phage-based diagnostics

Contact Us
BIVDA member 2023

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!